Regorafenib alone or in combination with high/low-dose radiotherapy plus toripalimab as third-line treatment in patients with metastatic colorectal cancer: protocol for a prospective, randomized, controlled phase II clinical trial (SLOT)

Combination strategies to improve immunotherapy response in microsatellite stable metastatic colorectal cancer (MSS mCRC) remain an unmet need. Several single-arm clinical trials have shown promising synergistic effects between regorafenib and ICIs; however, some contradictory results have also been...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shujuan, Wang, Chenchen, Shen, Lijun, Wang, Yan, Zhang, Hui, Wu, Ruiyan, Wang, Yaqi, Chen, Yajie, Xuan, Yan, Xia, Fan, Zhang, Zhen, Wan, Juefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586789/
https://www.ncbi.nlm.nih.gov/pubmed/37869085
http://dx.doi.org/10.3389/fonc.2023.1274487

Ejemplares similares

Ejemplares similares